New Jersey, USA-based Advaxis has entered into a formal business agreement with the Sage Group to introduce potential partnership candidates and develop new licensing opportunities. The Sage Group is a provider of strategic and transactional consultancy services to US and European health care and life science companies advising on global strategic partnering opportunities.
"With the increasing acceptance of our technology in the experimental medical community, it is an opportune time to identify possible strategic relationships," noted Advaxis chief executive Thomas Moore. "As our current licensing negotiations develop, we also seek to find additional opportunities to commercialize our platform as expeditiously as possible, and the Sage Group's expertise will help us find the best fit among potential partners, both near and long term," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze